122 related articles for article (PubMed ID: 25432160)
1. Identification of diphtheria toxin R domain mutants with enhanced inhibitory activity against HB-EGF.
Suzuki K; Mizushima H; Abe H; Iwamoto R; Nakamura H; Mekada E
J Biochem; 2015 May; 157(5):331-43. PubMed ID: 25432160
[TBL] [Abstract][Full Text] [Related]
2. Super-resolution microscopy unveils transmembrane domain-mediated internalization of cross-reacting material 197 into diphtheria toxin-resistant mouse J774A.1 cells and primary rat fibroblasts in vitro.
Fellermann M; Wondany F; Carle S; Nemeth J; Sadhanasatish T; Frick M; Barth H; Michaelis J
Arch Toxicol; 2020 May; 94(5):1753-1761. PubMed ID: 32266418
[TBL] [Abstract][Full Text] [Related]
3. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity.
Mitamura T; Higashiyama S; Taniguchi N; Klagsbrun M; Mekada E
J Biol Chem; 1995 Jan; 270(3):1015-9. PubMed ID: 7836353
[TBL] [Abstract][Full Text] [Related]
4. Diphtheria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its anti-tumorigenic activity.
Kageyama T; Ohishi M; Miyamoto S; Mizushima H; Iwamoto R; Mekada E
J Biochem; 2007 Jul; 142(1):95-104. PubMed ID: 17525101
[TBL] [Abstract][Full Text] [Related]
5. Receptor-based antidote for diphtheria.
Cha JH; Brooke JS; Chang MY; Eidels L
Infect Immun; 2002 May; 70(5):2344-50. PubMed ID: 11953369
[TBL] [Abstract][Full Text] [Related]
6. Ectodomain shedding of HB-EGF: a potential target for cancer therapy.
Miyazono K
J Biochem; 2012 Jan; 151(1):1-3. PubMed ID: 21976708
[TBL] [Abstract][Full Text] [Related]
7. Peptides derived from a short stretch of diphtheria toxin bind to heparin-binding epidermal growth factor-like growth factor.
Agarwal M; Mondal T; Bose B
Toxicon; 2019 Nov; 169():109-116. PubMed ID: 31494209
[TBL] [Abstract][Full Text] [Related]
8. Toxin binding site of the diphtheria toxin receptor: loss and gain of diphtheria toxin binding of monkey and mouse heparin-binding, epidermal growth factor-like growth factor precursors by reciprocal site-directed mutagenesis.
Cha JH; Brooke JS; Eidels L
Mol Microbiol; 1998 Sep; 29(5):1275-84. PubMed ID: 9767594
[TBL] [Abstract][Full Text] [Related]
9. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.
Yagi H; Yotsumoto F; Sonoda K; Kuroki M; Mekada E; Miyamoto S
Int J Cancer; 2009 Mar; 124(6):1429-39. PubMed ID: 19048624
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the biological activities of the epidermal growth factor (EGF)-like domain by the heparin-binding domain of heparin-binding EGF-like Growth Factor.
Takazaki R; Shishido Y; Iwamoto R; Mekada E
J Biol Chem; 2004 Nov; 279(45):47335-43. PubMed ID: 15331606
[TBL] [Abstract][Full Text] [Related]
11. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
Tang XH; Li M; Deng S; Lu MS
Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profile of human colon cancer cells treated with cross-reacting material 197, a diphtheria toxin non-toxic mutant.
Rivetti S; Lauriola M; Voltattorni M; Bianchini M; Martini D; Ceccarelli C; Palmieri A; Mattei G; Franchi M; Ugolini G; Rosati G; Montroni I; Taffurelli M; Solmi R
Int J Immunopathol Pharmacol; 2011; 24(3):639-49. PubMed ID: 21978696
[TBL] [Abstract][Full Text] [Related]
13. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
[TBL] [Abstract][Full Text] [Related]
14. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
[TBL] [Abstract][Full Text] [Related]
15. Binding properties of diphtheria toxin to cells are altered by mutation in the fragment A domain.
Mekada E; Uchida T
J Biol Chem; 1985 Oct; 260(22):12148-53. PubMed ID: 4044590
[TBL] [Abstract][Full Text] [Related]
16. Single mutation in the A domain of diphtheria toxin results in a protein with altered membrane insertion behavior.
Hu VW; Holmes RK
Biochim Biophys Acta; 1987 Aug; 902(1):24-30. PubMed ID: 3607056
[TBL] [Abstract][Full Text] [Related]
17. [Cytotoxicity of the B subunit of diphtheria toxin to human histocytic lymphoma U937].
Korotkevych NV; Labyntsev AIu; Kaberniuk AA; Oliĭnyk OS; Romaniuk SI; Kolybo DV; Komisarenko SV
Ukr Biokhim Zh (1999); 2009; 81(4):69-80. PubMed ID: 20387636
[TBL] [Abstract][Full Text] [Related]
18. Receptor-Mediated Enhanced Cellular Delivery of Nanoparticles Using Recombinant Receptor-Binding Domain of Diphtheria Toxin.
Agarwal M; Sahoo AK; Bose B
Mol Pharm; 2017 Jan; 14(1):23-30. PubMed ID: 27959571
[TBL] [Abstract][Full Text] [Related]
19. Validity of HB-EGF as Target for Human Neuroblastoma Therapy.
Nam SO; Yotsumoto F; Miyata K; Souzaki R; Taguchi T; Kuroki M; Miyamoto S
Anticancer Res; 2015 Aug; 35(8):4433-40. PubMed ID: 26168483
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia.
Kunami N; Yotsumoto F; Ishitsuka K; Fukami T; Odawara T; Manabe S; Ishikawa T; Tamura K; Kuroki M; Miyamoto S
Anticancer Res; 2011 Jul; 31(7):2483-8. PubMed ID: 21873163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
